These innovative compounds represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a triple GLP-1 and GIP receptor agonist, demonstrates promising efficacy in reducing blood glucose levels. https://aruncenh169850.buyoutblog.com/39116576/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide